- Home
- PHAR vs SLQT Comparison
PHAR vs SLQT Comparison
Compare PHAR & SLQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- SLQT
- Stock Information
- Founded
- PHAR 1988
- SLQT 1999
- Country
- PHAR Netherlands
- SLQT United States
- Employees
- PHAR N/A
- SLQT N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- SLQT Specialty Insurers
- Sector
- PHAR Health Care
- SLQT Finance
- Exchange
- PHAR Nasdaq
- SLQT Nasdaq
- Market Cap
- PHAR 718.1M
- SLQT 386.9M
- IPO Year
- PHAR N/A
- SLQT 2020
- Fundamental
- Price
- PHAR $10.27
- SLQT $2.39
- Analyst Decision
- PHAR Strong Buy
- SLQT Hold
- Analyst Count
- PHAR 3
- SLQT 2
- Target Price
- PHAR $30.00
- SLQT $3.38
- AVG Volume (30 Days)
- PHAR 4.3K
- SLQT 898.0K
- Earning Date
- PHAR 07-31-2025
- SLQT 05-12-2025
- Dividend Yield
- PHAR N/A
- SLQT N/A
- EPS Growth
- PHAR N/A
- SLQT N/A
- EPS
- PHAR N/A
- SLQT N/A
- Revenue
- PHAR $320,708,000.00
- SLQT $1,488,701,000.00
- Revenue This Year
- PHAR $13.31
- SLQT $17.72
- Revenue Next Year
- PHAR $7.68
- SLQT $13.05
- P/E Ratio
- PHAR N/A
- SLQT N/A
- Revenue Growth
- PHAR 24.13
- SLQT 20.41
- 52 Week Low
- PHAR $6.65
- SLQT $1.62
- 52 Week High
- PHAR $12.61
- SLQT $6.86
- Technical
- Relative Strength Index (RSI)
- PHAR 48.21
- SLQT 54.86
- Support Level
- PHAR $10.46
- SLQT $2.25
- Resistance Level
- PHAR $11.49
- SLQT $2.53
- Average True Range (ATR)
- PHAR 0.37
- SLQT 0.10
- MACD
- PHAR -0.12
- SLQT 0.04
- Stochastic Oscillator
- PHAR 27.62
- SLQT 73.47
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About SLQT SelectQuote Inc.
SelectQuote Inc is a Direct-to-consumer (DTC) distribution platform which facilitates consumers to shop for health, life and auto & home insurance policies online. The company generates its revenues by selling insurance products on behalf of the insurance carrier partners in the form of a commission. It has four reportable segments namely Senior, Healthcare Services, Life, and Auto & Home. It functions through three lines namely, SelectQuote Senior, SelectQuote Life, and SelectQuote Auto & Home.